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Abstract
Background: Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low
doses to treat malaria. A phase I evaluation was conducted to assess the safety and pharmacokinetic profile of this
drug in healthy adult male Kenyan volunteers.
Methods: Twenty five healthy adult volunteers were recruited and admitted to receive a 5 mg dose of
methotrexate/day/5 days. Pharmacokinetics blood sampling was carried out at 2, 4, 6, 12 and 24 hours following
each dose. Nausea, vomiting, oral ulcers and other adverse events were solicited during follow up of 42 days.
Results: The mean age of participants was 23.9 ± 3.3 years. Adherence to protocol was 100%. No grade 3 solicited
adverse events were observed. However, one case of transiently elevated liver enzymes, and one serious adverse
event (not related to the product) were reported. The maximum concentration (Cmax) was 160-200 nM and after 6
hours, the effective concentration (Ceff) was <150 nM.
Conclusion: Low-dose methotraxate had an acceptable safety profile. However, methotrexate blood levels did not
reach the desirable Ceff of 250-400-nM required to clear malaria infection in vivo. Further dose finding and safety
studies are necessary to confirm suitability of this drug as an anti-malarial agent.
Background
Chemotherapy remains one of the most important tools
for the management and control of malaria. The World
Health Organization has recommended the use of artemi-
sinin combination therapy (ACTs) as first-line treatments
of uncomplicated malaria; ACT is also used for the treat-
ment of malaria in pregnancy during the second and
third trimesters [1]. Artemether-lumefantrine is the first
ACT to be introduced in Africa [1]. Pyronaridine/artesu-
nate and pipepraquine/dihydroartemesin are in the late
development stages and have reached Phase III/IV clini-
cal evaluation [2]. The artemisinin derivative artesunate
has been recommended as a drug choice for the treat-
ment of severe malaria, in replacement quinine [3]. How-
ever, the emergence of Plasmodium falciparum parasite
resistant to artemisinin derivatives has been reported in
South Asia, and there is concern that this would spread
to Africa, which would compromise the current ACT
strategy and the use of artesunate in severe malaria [4].
Quinine has become the second-line of treatment of
uncomplicated malaria in many countries [1]. However,
evidence indicates that resistance to this drug is also
spreading in South Asia [5]. Thus, to counterbalance this
burgeoning drug resistance problem, new drugs are
urgently needed.
Several investigators have demonstrated that the anti-
cancer methotrexate (MTX) and trimetrexate (TMX),
which are inhibitors of dihydrofolate reductase (DHFR),
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and PM-resistant P. falciparum strains (parasites har-
boring wild type or mutant dhfr respectively), including
those carrying the Ileu-164-Leu dhfr codon, with IC50 <
85 nM (inhibitory concentration that kill 50% of parasi-
taemia) [6-10].
MTX is used at high dose, up to 5 to 24 g per adult
per week (130-300 mg/kg) for several weeks for the
treatment of cancer. This dose can yield serum concen-
trations of >1000 μM, a concentration range associated
with MTX life-threatening toxicity [11]. By contrast, a
1000-fold lower dose of MTX (LD-MTX) [0.1-0.4 mg/kg
(7.5-30 mg per adult)] is used once weekly in the treat-
ment of rheumatoid arthritis (RA), juvenile idiopathic
arthritis (JIA) in children (including infants <one year
old) and psoriasis [12-14]. This use of LD-MTX is rela-
tively safe and well tolerated, and children tolerate it
better than adults [14]. Pharmacokinetic data indicate
that LD-MTX yields in vivo concentrations >250 nM,
which can clear malaria parasites in vivo (MTX IC99 of
200-400 nM) [15-17]. In addition, two old and small
clinical trials carried out in the 1970 s, indicated that
LD-MTX, as low as 2.5 mg per dose per day, was safe
and efficacious to treat P. falciparum and Plasmodium
vivax in adults [18,19]. Taken together, this information
has led us to re-evaluate the potential of LD-MTX as
anti-malarial. The literature is replete with similar exam-
ples of the use of anti-cancers at low and safe dose for
the treatment of non-neoplastic diseases [20].
This is a report of a clinical trial of LD-MTX in
healthy adult Kenyans to assess its safety, tolerability
and pharmacokinetics, as a step towards its development
for the treatment of uncomplicated falciparum malaria.
This trial was registered at ClinTrials.gov (NCT#
00791531). As started earlier, a dose as low as 2.5 mg/
day for 3 to 5 days was found to clear malaria infection,
and the use of MTX in arthritis indicates that 7.5-30 mg
per week was relatively safe. Thus, a dose of 5 mg/day/5
days (for a total of 25 mg per week) was chosen for
investigation since it did not exceed 30 mg per treat-
ment (the weekly dose used in arthritis), and was double
the 2.5 mg/day (previously tested in malaria).
Methods
The study was conducted between 3
rd March 2009 and
31
st August 2009 at the Kenya Medical Research Insti-
tute (KEMRI), Nairobi. After obtaining all the required
ethical approvals, the study was advertised using posters
and word of mouth with messages from the approved
subject information sheets. The study nurses obtained
informed consent from the study participants, after
which recruitment into the study began. The partici-
pants underwent pre-HIV test counselling, full physical
examination and a baseline blood sample was taken.
They were advised to report to the study clinic the fol-
lowing day, ready for admission in the study ward for 5
days, if they met the eligibility criteria. The day of
admission was considered as day 0 for each volunteer.
Only eligible volunteers were assigned a unique study
identification (ID) number, which was linked to a pre-
generated random allocation to the pharmacokinetics
(PK) sampling group.
This study was reviewed and approved by the KEMRI
Scientific Steering Committee, KEMRI/National Ethical
Review Committee (ERC), Pharmacy and Poisons Board,
Kenya and the Oxford Tropical Research Ethics Com-
mittee (OXTREC number 5608). The study was con-
ducted in compliance with ICH-GCP guidelines and the
Declaration of Helsinki, 2008 [21,22].
Study population and follow up
The study population was a group of 25 healthy adult
male volunteers screened from communities living
around the KEMRI facility in Nairobi. A summary of
the inclusion and exclusion criteria applied to this study
is shown in Table 1. Eligible volunteers were adminis-
tered 5 mg of MTX daily orally under observation. All
volunteers were discharged on day 5 and follow up visits
were on days 7, 14, 28 and 42. Figure 1 shows the study
flow chart.
Investigational product
MTX was purchased from Wyeth Pharmaceuticals
(South Africa) as 2.5 mg tablets, with a shelf-life of
three years. The drug was stored in a dry, locked cabinet
at a temperature below 30°C and it was used according
Table 1 Summary of inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
Male aged ≥18 -≤55 years
old;
Weighing 50-75 kg
Haemoglobin ≥10 g/dl
HIV negative
Written informed consent
from the study subject.
Severe underlying conditions such as
malnutrition, clinically suspected cardiac,
renal, or hepatic diseases, suspected
AIDS, or severe injury.
Presence of any concomitant illnesses
such as malaria, lower respiratory tract
infections (LRTI), acute bloody or non-
bloody diarrhoeas, or other acute
infections.
History of treatment with antimalarial
drugs within the last 2 weeks.
History of treatment with aspirin or any
non-steroidal-anti-inflammatory agent or
trimethoprim and co-trimoxazole within
the last 7 days.
Any ongoing medication.
Abnormal clinical chemistry or
hematological finding.
Alcohol/drugs intake.
Any other reason in the recruiting
clinician’s opinion that makes the
individual unsuitable for taking part in a
clinical trial.
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Page 2 of 9to the manufacturer’s specifications. At each dosing time
point, two tablets were administered with water in the
morning before breakfast every day for five days.
Pharmacokinetics (PK), blood Sampling and measurement
of MTX concentrations
The 25 study ID numbers were randomly pre-allocated
(using a computer-generated simple randomization list)
to five groups of five participants in each group. This
allocation ensured that on each day, only one group of
five participants was scheduled to give blood sample
(2 ml) at 2, 4, 6, 12 and 24 hours after each daily MTX
dose administration for PK study. Blood samples were
c o l l e c t e di nE D T At u b e sa n ds t o r e da t- 2 0 ° C .S a m p l e s
were later transported to the KEMRI-Wellcome Trust
Programme, Kilifi for analysis. Plasma concentrations of
MTX were measured using Abbott TDx FLx fluorescence
polarisation immunoassay analyser (Abbott Diagnostics,
IL, USA). The MTX II reagent, calibrator and control
kits, and diluent buffer were supplied by the manufac-
turer. The inter-assay coefficients of variation over the
range of low (0.07 μmol/L), medium (0.4 μmol/L) and
high (0.8 μmol/L) concentrations of the quality control
standards were 9.23, 3.95 and 3.32% (n = 12 in all cases),
respectively. Pharmacokinetic parameters calculated were
maximum concentration (Cmax), half-life (T1/2) and area
under the curve (AUC).
Clinical safety evaluation and reporting of adverse event
Volunteers were clinically assessed before administration
of each dose of study medication and on the scheduled
clinic visits on days 7, 14, 28 and 42, and they were
advised to return to the facility at any time when they
did not feel well. The definitions for adverse events
(AE); serious adverse events (SAE) and suspected unex-
pected serious adverse reactions (SUSARs) were used
according to standard ICH-GCP [22]. SAE’s, including
SUSAR’s were to be reported by telephone and email to
the local safety monitor and sponsor within 24 hours of
becoming aware of the event. The ERC and Pharmacy
and Poison’s Board (PPB), the regulatory authority were
notified within a week.
Assessed for eligibility (n=60  )
Excluded  (n=  35 )
¨ Not meeting inclusion criteria (n=20 )
¨ Declined admission (n= 11 )
¨ Other reasons (n= 4 )
Analysed  (n= 25 )
¨ Excluded from analysis (give reasons) (n= 0 )
Day 0 
PK sampling (n= 5)
Allocated to intervention (n=  25)
Received allocated intervention (n25 )
¨ Did not receive allocated intervention (give 
reasons) (n= 0 )
¨ Randomized  PK sampling group (n = 5)
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Day 3
PK sampling (n= 5)
Day 4
PK sampling (n= 5)
Completely follow up according to protocol  (n= 25  )
¨ Discontinued intervention (give reasons) (n= 0 )
Figure 1 Study flow chart.
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on blood samples collected in EDTA and heparinized
tubes for haematology/biochemistry and PK respectively.
A, BECKMAN Coulter™ (model AC.T 5 Diff CP; Florida,
USA) haematology analyzer was used with manufacturer
reagents to estimate total white cell count, red cell count
and haemoglobin levels. A Selectra (model E VitaLab™,
The Netherlands) chemistry analyser with reagents from
Randox™ (Ireland) was used to measure creatinine, ala-
nine aminotransferase (ALT), aspertate aminotransferase
(AST), alkaline phosphatase (ALP) and total bilirubin.
No formal sample size calculation was done, since this
was a descriptive phase I safety study. However, because
of PK considerations requiring population sampling for
at least five time-points, the sample size of 25 was
adopted to allow for 5 concentration-time data points
for each blood sampling time-point.
Data management and statistical methods
Because the trial involved healthy volunteers with no
medical records, specific participant files were used to
capture all information as source. Data was then tran-
scribed on to case record files, which were checked by
the monitors at 100% verification against the source
documents. The case records where then reviewed for
completeness by the data manager before entry on to
the study database.
OpenClinica™ (an open source, GCP compliant data
management system provided by Akaza Research, LLC,
MA. USA), running on Microsoft Windows Server 2003,
Apache Tomcat™ ( a no p e ns o u r c ew e bs e r v e rb y
Apache Software Foundation, California, USA) and Post-
greSQL™ (open source database by PostgreSQL Global
Development Group, USA) was used for setting up and
managing the clinical trial data.
Standard statistical analyses, based on the review of
the individual values of clinically significance variables
and descriptive statistics (summary tables, graphs) were
conducted using the data analysis and statistical pro-
gramme, STATA (version 11); StataCorp LP, Texas,
USA. Non-parametric methods were used to assess for
any statistically significant changes of the clinical labora-
tory safety parameters.
Results
At total of 60 adult male volunteers were screened, out of
which 25 with mean age of 23.9 ± 3.3 years were enrolled
in the study. Other baseline demographic characteristics
collected included height, weight and body mass index
(BMI), and are summarized in Table 2. A 100% protocol
compliance, medication and follow-up to study proce-
dures were achieved.
Among the solicited adversee v e n t s ,o n l yn a u s e aw a s
observed in 1/25 (4%) participant between days 3 and 7.
Neither oral ulcers nor vomiting were reported at any
time during the trial period. For other unsolicited symp-
toms, the following were reported: dizziness 2/25 (8%)
and diarrhoea 1/25 (4%), and headache 3/25 (12%), and
they all occurred between day 0 and 2. No other non-
serious AEs were reported at follow up times till day 28
when one volunteer reported headache, diarrhoea and
abdominal pains, and another volunteer complained of
headache on day 42. All these events resolved without
sequelae.
One serious adverse event was reported on day 21. The
volunteer was brought to the study clinic and admitted in
the ward in a semi-comatose state, with cough and fever.
The diagnosis was right-sided lobar pneumonia with
X-ray evidence of lung consolidation, which was treated
with parenteral crystalline penicillin. He fully recovered
and was discharged after three days without any further
complications. This serious adverse event was deemed to
be unrelated to the study medication.
For the haematological profiles, there was in general, a
trend towards a mild decrease in haemoglobin, red cell
count and total white blood cell count, during the first
week following drug administration. However, these
levels normalised by week 2-3, except those of the total
w h i t ec e l lc o u n t ,w h i c h ,a l t hough remained within nor-
mal ranges, showed a statistically significant declining
trend (P = 0.025). However, all these events were with-
out any clinically significant outcome (Figure 2).
Liver enzymes (AST, ALT, ALP) and total bilirubin levels
tended to increase during the first week, and by the fourth
week, the levels returned to normal values (Figure 3). How-
ever, one participant experienced a high (grade 3) rise in
AST by up to 4.8 times and ALT 13 times higher than nor-
mal by day 7. The participant was clinically stable and
asymptomatic; these abnormal parameters all returned to
Table 2 Baseline demographic characteristics
Parameters Mean (SD)
Age (years) 23.92 (3.33)
Height (cm) 172.2 (5.14)
Weight (kg) 60.78 (4.92)
Body Mass Index (BMI) 20.5 (1.58)
Respiratory rate (breaths per min) 18.25 (0.68)
Heart rate (beats per min) 68.54 (8.57)
Systolic blood pressure (mmHg) 115.92 (7.73)
Haemoglobin level (g/dL) 16.12 (1.36)
RBC (per μL) 5.62 (0.53)
WBC (per μL) 5.69 (1.39)
ALT Test (units) 24.2 (9.58)
AST Test (units) 36.65 (13.81)
ALP Test (units) 179.35 (49.14)
Creatinine (units) 102.85 (18.83)
Total bilirubin (units 11.33 (6.20)
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28. Further investigations on any liver pathology that could
potentially explain the result (including detailed medical
history probing, any alcohol consumption, blood sugar and
screening for hepatitis A and B) was negative.
PK analysis of LD-MTX (5 mg/day for 5 days) showed
that Cmax ranged from 160-200 nM, and these levels
were achieved within the first hour. Thereafter, concen-
trations rapidly declined and the effective concentration
(Ceff) was <150 nM after 6 hours, following drug admin-
istration (Figure 4). These levels are lower than the
reported IC99, which is around 200-400 nM. The concen-
trations were consistently less than 50 nM by 24 hours
post dose (Figure 4). The geometric means for Cmax
and area under the curve from 0 to 24 H (AUC0-24 H)o n
day 0 were 170 and 959 nmoles hours/L, respectively,
compared with 145 and 936 nmoles hours/L, respectively,
on day 4. These results suggest that MTX does not accu-
mulate in the body following repeated administration of
the LD-MTX over 5 days. Drug levels for each partici-
pant are given in Additional file 1.
Discussion
LD-MTX, at doses between 7.5-30 mg/adult per week
for several years has been extensively used in the wes-
tern world for the treatment inflammatory diseases
including RA, JIA and psoriasis [12-14]. At this dose
and regime, the drug is safe and well tolerated. These
data confirm the safety profile of LD-MTX at 5 mg/day/
5 days in an African population.
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Page 5 of 9The use of MTX is known to mildly increase liver
enzymes, and the levels always normalise within a few
weeks after drug discontinuation [23,24]. Thus, the
increase in liver enzyme levels we observed was
expected, and they were all normalised within four
weeks, as the data show. One participant however
experienced excessively high AST and ALT enzyme
levels. In the treatment of inflammatory diseases, such
high rises in liver enzymes are rare, and in most cases,
they are the result of the pre-existing liver infections
s u c ha sh e p a t i t i sA ,B ,C ,D ,E ,G ,A d e n o v i r u s e s ,
Epstein-Barr-virus, among others; alcohol use, obesity
and diabetes can also contribute to a higher rise of liver
enzymes [23,24]. Although all possible causes were not
investigated, the following could be excluded: alcohol
use, obesity, diabetes and hepatotropic virus infections,
such as hepatitis A and B. Nevertheless, at day 28, the
key study time point, the levels in the volunteer had
normalized, and he never experienced any clinical symp-
toms. Overall, a significant mild decrease in white cell
was observed up to day 42. It is well known that the use
of LD-MTX is associated with decrease in haematologi-
cal parameters (haemogloglin, red blood cells and white
cells), however the levels normalized within few weeks
after the end of treatment [12,13]. In the current study,
white cell count were significantly decreased, but the
levels were still within the normal reference ranges, and
had no clinical significance. Nevertheless, this parameter
should be closely monitored in all subsequent clinical
evaluations of this drug.
LD-MTX is increasingly being used in Africa [25],
including in Kenya [26] for the treatment of RA, JIA
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Page 6 of 9and psoriasis. In these situations, liver enzymes are
monitored regularly as part of the management of LD-
MTX treatment. In Kenya, more than 100 patients are
or had been under LD-MTX treatment for several
months, and no such high levels of liver enzymes has
been reported (G.O. Oyoo, unpublished). Thus, it is
clear that enzyme levels should be monitored closely in
all our subsequent clinical evaluation of LD-MTX.
LD-MTX is also being used in the treatment of var-
ious disease conditions including: inflammatory bowel
disease [27]; urticaria ([28] ankylosing spondylitis [29];
idiopathic hypertrophic cranial pachymeningitis [30];
chronic cholestatic disorder ([31]; Wegener’s granuloma-
tosis [32]; primary biliary cirrhosis [33]; systemic lupus
erythematosus [34]; and inflammatory eye disease [35],
haemophagocytic lymphohistiocytosis, a disease that
affects younger children, including infants (<12 months
of age) [36]. Worldwide, it is estimated that 0.5-1 mil-
lion adults and 50,000-100,000 children receive LD-
MTX weekly for the treatment of RA, JIA respectively.
T h em o s tc o m m o n l yr e p o r t e dL D - M T Xs i d ee f f e c t sa r e
nausea, vomiting, diarrhoea and oral ulcers. These side
effects were solicited in this trial, and as the observa-
tions indicate, they were not commonly found at the
5 mg/day dose in the study cohort. This was expected
indeed as it is well known that LD-MTX adverse effects
are the result of the chronic use of the drug, and these
symptoms are generally observed after several weeks of
therapy. LD-MTX in this study was used for 5 days
only, thus it is not surprising that these adverse effects
were rare. In RA, JIA and psoriasis, folate derivatives are
administered in some patients to lower these effects.
However, the five-day drug regimen did not warrant use
of folate derivatives. Thus, for treatment of uncompli-
cated malaria, LD-MTX could indeed be used alone as
we proposed.
In previous work, MTX IC50 around 40-85 nM were
reported these values correspond to IC99 around 200-400
nM [6,37], thus Ceff of MTX >400 nM should achieved
to clear malaria infection. However our PK analysis
shows that the achieved mean Cmax was around 200 nM
only, and after 6 hours, MTX concentrations declined
below 150 nM. These concentrations are not high
enough to clear malaria infection; concentrations above
400 nM for 6-12 hours would need to be achieved. This
implies that further studies should be carried out to eval-
uate the dose range that will yield adequate plasma con-
centrations and still be well tolerated. One of the
approaches would be to reduce the days of treatment
from 5 to 3 only, and increase the dose to 7.5, 10 or 12.5
mg per day. The total dose for each treatment course
should however remain around 22.5-37 mg, which is
close to the range of doses administered weekly in the
treatment of inflammatory diseases (7.5-35 mg per adult).
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Figure 4 Methotrexate (MTX) plasma concentration from day 0 to day 4. Five participant provided blood each day, thus each point
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safe since its toxicity is mainly the result of chronic use,
while in the case of malaria treatment, it would be used
for three days only. Another approach could be to start
with a loading dose of 10 to 15 mg for the first day, and
subsequently use lower doses to 5 or 7.5 mg, a strategy
similarly used with quinine and artemether/lumefantrine
in the treatment of severe and uncomplicated malaria,
respectively [1].
In conclusion, 5 mg of MTX/day for 5 days is safe and
well tolerated. However, MTX blood levels achieved are
not high enough to clear malaria infection. Therefore,
other dose ranging clinical investigation need to be car-
ried out to establish the optimal doses that are safe and
can yield adequate MTX concentrations in the body.
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